$36.79
▲ +0.6% Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 0
● 21
▼ 1
Artisan Sold Medline (MDLN) as Cost Pressures Delayed the Company’s Profit Recovery
Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
Tigress Financial Adjusts Medline Price Target to $55 From $62, Maintains Buy Rating
Overview
52-week range
$32
$51
23% of range
Avg surprise (last 1)
+13.8%
Avg reaction (last 1)
-7.3%
0% positive
Latest IV / EM
40%
EM ±6.3% · $38 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Sat Jun 27, 2026 | Jun 2026 | $0.07 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $0.33 | $0.29 | +13.8% | — | -7.3% | earnings |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | $7.68B | $7.35B | — | $6.89B | $6.64B |
| Cost of revenue | $5.47B | $5.51B | — | $4.98B | $4.82B |
| Gross profit | $2.21B | $1.84B | — | $1.91B | $1.82B |
| Operating income | $395M | $422M | — | $642M | $571M |
| Net income | $139M | $239M | — | $329M | $319M |
| EPS (diluted) | $0.07 | $0.16 | — | — | — |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $2.33B | $2.24B | $1.94B | — | — |
| Inventory | $4.67B | $4.81B | $4.77B | — | — |
| Total current assets | $11.74B | $11.18B | $10.68B | — | — |
| Total assets | $39.35B | $39.01B | $38.48B | — | — |
| Long-term debt | $12.55B | $12.49B | $12.48B | — | — |
| Total liabilities | $20.27B | $19.66B | $19.20B | — | — |
| Total equity | $11.57B | $19.35B | $10.74B | — | — |